Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + pirarubicin
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Intravesical
01
Overview
Epirubicin + pirarubicin is a combination of two anthracycline chemotherapy agents, both of which are small molecule drugs used primarily in the treatment of various cancers. Epirubicin and pirarubicin act by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and preventing cancer cell replication. Both drugs are known for their antitumor activity, with epirubicin commonly used in breast cancer and other solid tumors, while pirarubicin is also indicated for breast cancer, bladder cancer, and certain lymphomas. The combination may be considered investigational or off-label; it has been studied in preclinical models for enhanced antitumor effects[2][4][6].
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on epirubicin + pirarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + pirarubicin.